# Treatment of hepatocellular carcinoma with gluteus medius metastasis: a case report and a literature review

**Authors:** Yanxin Li, Ji Luo, Jianyong Zhang, Mingqiang Sun, Jinping Yang

PMC · DOI: 10.3389/fonc.2025.1329756 · Frontiers in Oncology · 2025-05-01

## TL;DR

A case report shows successful use of interstitial brachytherapy to treat a rare muscle metastasis from liver cancer, offering symptom relief and local control.

## Contribution

The first reported use of interstitial brachytherapy for gluteus medius metastasis from hepatocellular carcinoma.

## Key findings

- Interstitial brachytherapy achieved good local control of the metastatic tumor.
- The treatment provided significant symptom relief for the patient.
- This case suggests a potential new application for brachytherapy in rare cancer metastases.

## Abstract

Hepatocellular carcinoma (HCC) accounts for 85%–90% of all primary liver cancers (PLCs). Owing to the occult nature of HCC, most patients present at an advanced stage at the time of initial diagnosis and have a poor prognosis. With regard to systemic therapy, targeted therapy and immunotherapy are currently the centers of clinical research. With regard to local treatment, surgical resection, radiofrequency ablation, hepatic artery chemoembolization, and radiotherapy are commonly used. Interstitial brachytherapy is commonly used for the treatment of cervical and genitourinary cancers. In this case, interstitial brachytherapy was used to treat gluteus medius muscle metastasis from PLC, with good local control and symptom relief.

## Linked entities

- **Diseases:** hepatocellular carcinoma (MONDO:0007256)

## Full-text entities

- **Genes:** CHGA (chromogranin A) [NCBI Gene 1113] {aka CGA, PHE5, PHES}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, CD34 (CD34 molecule) [NCBI Gene 947], GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, SYNM (synemin) [NCBI Gene 23336] {aka DMN, SYN}
- **Diseases:** diplopia (MESH:D004172), numbness (MESH:D006987), cervical and genitourinary cancers (MESH:D014565), PLC (MESH:C537875), trauma (MESH:D014947), exophthalmos (MESH:D005094), liver cirrhosis (MESH:D008103), cervical cancer (MESH:D002583), death (MESH:D003643), chronic hepatitis B (MESH:D019694), pain (MESH:D010146), cancer (MESH:D009369), HCC (MESH:D006528), back pain (MESH:D001416), depression (MESH:D003866), metastases (MESH:D009362), liver tumors (MESH:D008113), RILD (MESH:D007953), cervical, prostate, and breast cancers (MESH:D011471), portal hypertension (MESH:D006975), paraplegia (MESH:D010264), muscle (MESH:D019042), osteosarcoma (MESH:D012516), viral hepatitis (MESH:D014777)
- **Chemicals:** entecavir (MESH:C413685), sintilimab (MESH:C000632826), iridium-192 (MESH:C000615087), cobalt-60 (MESH:C000615395), sorafenib (MESH:D000077157), aflatoxins (MESH:D000348), lenvatinib mesilate (MESH:C531958)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12079037/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12079037/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12079037/full.md

---
Source: https://tomesphere.com/paper/PMC12079037